Altium Capital Management LP has recently announced that it has increased stake in Immunic Inc. (NASDAQ:IMUX) by 18.06%. After grabbing 1.11 million shares, the institutional investor is now in possession of 0.17 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 7.42% having worth around $19.11 million. Moreover, The Vanguard Group, Inc. increased its share by 0.23 million to have a control over 0.24 million shares. And Granite Point Capital Management.. raised its holdings to 0.2 million shares by acquiring 0.2 million shares or 1.32% of the stake.
Immunic Inc. (IMUX) concluded trading on 08/26/20 at a closing price of $16.76, with 1.71 million shares of worth about $28.74 million changed hands on the day. Weekly performance of the stock remained negative as price took a plunge of -13.61% during that period and on Wednesday the price saw a gain of about 16.23%. Currently the company’s common shares owned by public are about 12.70M shares, out of which, 7.18M shares are available for trading.
Analysts also issued an outlook of 1.50 for the Immunic Inc. stock for next 12 months.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 8 times over the past 12 months. They bought 23,157 shares in 2 of the transactions. In 6 selling transactions, insiders dumped 24,280 shares.
Vanguard Total Stock Market Index, Fidelity Select Port. – Biotechno, and iShares Russell 2000 ETF are the top 3 mutual funds which are holding stakes in Immunic Inc. Vanguard Total Stock Market Index is currently holding 0.22 million shares of worth totaling $3.86 million. The company recently came buying 0.0 shares which brought its stake up to 1.50% of the company’s outstanding shares. iShares Russell 2000 ETF, after selling 77032.0 shares, have now control over 0.52% of the stake in the company. It holds 3570.0 shares of worth $1.32 million.
Immunic Inc. (NASDAQ: IMUX) started trading at $18.32, above $3.9 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $16.76, or with a gain of 16.23%. Stock saw a price change of -13.61% in past 5 days and over the past one month there was a price change of 3.78%. Year-to-date (YTD), IMUX shares are showing a performance of 72.78% which increased to 17.45% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.19 but also hit the highest price of $23.39 during that period. While comparing its average daily trading volume of 542.24K shares, we see that about 1.71 million changed hands on the day. The stock is currently trading -9.04% below its 20-day simple moving average (SMA20), while that difference is up 6.74% for SMA50 and it goes to 63.31% higher than SMA200.
Altium Capital Management LP acquired 1.11 million shares of Immunic Inc. having value of about $19.11 million. Data submitted at the U.S SEC by Altium Capital Management LP revealed that the firm now holds 0.17 million shares in the company valued at close to $2848093.84, or have control over 18.06% stake in the company. Immunic Inc. (NASDAQ: IMUX) currently have 12.70M outstanding shares and institutions hold larger chunk of about 25.40% of that. Holding of mutual funds in the company is about 4.00% while other institutional holders and individual stake holders have control over 4.36% and 22.49% of the stake respectively.
The stock has a current market capitalization of $339.39M and its 3Y-monthly beta is at 2.93. It has posted earnings per share of -$3.26 in the same period. It has Quick Ratio of 6.90 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IMUX, volatility over the week remained 11.00% while standing at 8.68% over the month.
Analysts are in expectations that Immunic Inc. (IMUX) stock would likely to be making an EPS of $McEwen Mining Inc. in the current quarter, while forecast for next quarter ESPS is $1.26 and it is $Stocks for next year. For the current quarter EPS, analysts have given the company a lowest target $Imax Corporation which is $IMTX at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $IMMUNOCELLULAR THERAPEUTICS LTD in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 88.40% while it is estimated to decrease by -4.90% in next year. EPS is likely to shrink at an annualized rate of 15.50% for next 5-years, compared to annual growth of 49.80% made by the stock over the past 5-years.
Analysts at 6 brokerage firms have issued recommendations for the Immunic Inc. (IMUX)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.50. Out of those 6 Wall Street analysts, 6 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on August 26, 2020 offering an Overweight rating for the stock and assigned a target price of $71 to it. Coverage by ROTH Capital stated Immunic Inc. (IMUX) stock as a Buy in their note to investors on August 07, 2020, suggesting a price target of $64 for the stock. On July 20, 2020, BMO Capital Markets Initiated their recommendations, while on June 05, 2020, Wedbush Initiated their ratings for the stock with a price target of $59. Stock get a Buy rating from H.C. Wainwright on May 11, 2020.